Robust IPO activity through late 2026 reflects a strong pipeline of scheduled listings and a substantial private-company backlog seeking liquidity, with multiple U.S. debuts already priced in October and additional filings advancing toward November. Record 2026 proceeds, driven by large transactions such as SpaceX, have exceeded prior years excluding outliers, though elevated 10-year Treasury yields near 5.3% and selective investor demand have prompted some postponements and valuation discipline. Key near-term catalysts include biotechnology and tech offerings in mid-October alongside expectations for a major AI-related debut before year-end, while macro factors such as monetary policy signals and aftermarket performance will influence deal flow into early 2027. Trader sentiment aggregates these confirmed listings and market conditions into high implied probabilities for additional IPOs before January 2027.